Bayer AG has filed a patent-infringement suit against Watson Pharmaceuticals and Sandoz, a subsidiary of Novartis AG, over generic versions of Yasmin, its oral contraceptive. The lawsuit prevents Sandoz and Watson from obtaining U.S. marketing clearance for their copies of the drug for as long as 30 months or until the dispute is settled, Watson said in a statement.

Full Story:
Forbes, Bloomberg

Related Summaries